BioNTech announced plans to establish a regional headquarters for Southeast Asia in Singapore, as well as a fully integrated mRNA manufacturing facility there with support from the Singapore Economic Development Board. The mRNA manufacturing facility will be equipped to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer. The planned site will offer highly automated and end-to-end mRNA production capabilities for active ingredients, drug products, and fill-and-finish, with an estimated annual capacity of several hundred million doses of mRNA-based vaccines, depending on the specific vaccine.
BioNTech plans to open its Singapore facility in 2021. The construction of the manufacturing plant is also expected to begin this year, subject to planning approval. The company expects the site could be operational as early as 2023 and will create up to 80 jobs in Singapore. BioNTech has already established a US headquarters in Cambridge, MA in 2020.
- BioNTech SE, Mainz, Germany
